Q2 FY26 Results: Revenue Down 40%, New Subsidiary Added

Revenue DeclineEbitda Margin CompressionResults View source PDF Explain this filing

SOLEX · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹1690.00

prior close

₹1609.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-4.7% vs market

Other Electrical Equipment peers, median of 42sector-0.6%-4.5% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.5 pts less than its Other Electrical Equipment peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0-0.4-4.7-0.6-4.5

Next day

-6.8-0.6-6.2-1.3-5.5

-8.6+0.3-8.9-1.5-7.1

-3.6+0.2-3.8-0.8-2.9

+1.2+0.1+1.1-1.0+2.2

+2.7+0.7+1.9-1.5+4.1

+8.1-0.3+8.4-2.6+10.7

15d

+0.7-2.0+2.7-3.5+4.2

-9.8-5.7-4.1-9.5-0.2

-34.3-7.8-26.5-14.9-19.4

-34.4-4.6-29.8-11.9-22.5

UpDownMarket · Nifty Microcap 250Sector · Other Electrical Equipment peers, median of 42Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Solex Energy reported Q2 FY26 consolidated revenue of Rs 15,502 lakhs, down 40 percent from Rs 25,967 lakhs in Q2 FY25. Consolidated profit fell to Rs 661 lakhs from Rs 3,033 lakhs. EPS dropped to Rs 3.74 from Rs 22.37. The company incorporated a new wholly owned subsidiary, Solex New Energy, on July 3, 2025 for solar cell manufacturing. Statutory auditor issued a clean limited review with no modifications. The company recently migrated from NSE Emerge to the NSE Main Board.

Likely market impact

Sharp Q2 revenue and profit decline may weigh on the stock. New subsidiary signals expansion into cell manufacturing.